Self-labeled Fusion Proteins for Ex Vivo Immunophenotyping of C-kit Receptor
Categories for this Invention
Biotechnology and Genetic Engineering | Drugs and Pharmaceutical Engineering
Industry: Healthcare, Pharma, Biotechnology
Application: Cancer diagnosis and prognosis, Immunophenotyping in leukemia and solid tumor, Allergy and autoimmune disorder diagnostics, Biomarker detection & monitoring, Drug development and personalized medicine
Market: Global Fusion Protein Market size was valued at USD 24.58 Billion in 2023 and is expected to reach USD 32.56 Billion by 2030, at a CAGR of 4.1% from 2023 to 2030.
Image Gallery
Problem Statement
- Current methods for detecting c-kit expression in cancer, allergies, and autoimmune disorders suffer from inconsistencies due to variations in antibodies and fluorochromes used.
- Antibody-based detection are complex, costly methods, poses immunogenicity issues.
- Standardization of c-kit expression detection is challenging due to heterogeneous results from different labs.
- Hence, there is a need for reliable alternative to antibody-based detection methods for accurate diagnosis and prognosis in cancer and related diseases.
Technology
The technology disclosure introduces a method for detecting expression of c-kit receptor, which is crucial in various diseases including cancer, allergies, and autoimmune disorders.
This antibody-based detection method utilizes self-labeled fusion proteins, consisting of stem cell factor (SCF) fused to SNAP-tag, allowing for covalent binding to detectable agent.
The Process Involves Following Steps:
Genetic Engineering:
- Fusion constructs of SCF fused to a SNAP tag are cloned into a mammalian vector.
Transfection:
- The fusion protein probe is transfected into host cells for genetic expression.
Purification:
- The expressed fusion protein probe is purified from the transfected culture.
Labeling:
- The probe is labeled with a detectable agent, typically benzylguanine or a derivative thereof with a fluorophore.
Key Features / Value Proposition
- Simplicity: The production process is simpler compared to antibody production.
- Cost-effectiveness: It is more cost-effective than antibody-based methods.
- Specificity: The fusion proteins exhibit high specificity for detecting c-kit expression.
- Stability: The SCF fused SNAP-tag is stable for extended periods, even at refrigerated temperatures.
Questions about this Technology?
Contact For Licensing
sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in
Research Lab
Prof. Rama S Verma
Department of Biotechnology
Intellectual Property
IITM IDF No: 1351
IN IP No: 415316 (Granted)
Technology Readiness Level
TRL – 4
Technology validated in lab.